Table 4.
Effects of Anti-COL17 NC16A Fabs on BP Autoantibody-Induced Mouse Model
| Abs used for reproducing mouse model | Treatment | Total dose of Fab (μg/g body weight) | Skin detachment |
|---|---|---|---|
| COL17 NC16A- affinity purified BP autoantibodies (BPAbs) | Fab-B4 | 15 | 2/8 |
| 30 | 0/10 | ||
| 30 (24 hours later) | 0/4 | ||
| 60 | 0/9 | ||
| Fab-19 | 15 | 2/6 | |
| 30 | 0/6 | ||
| 60 | 0/6 | ||
| Fab-106 | 15 | 5/5 | |
| 30 | 4/5 | ||
| 60 | 4/4 | ||
| Fab combination (Fab-B4 + 19 + 106) | 15 | 2/5 | |
| 30 | 0/6 | ||
| 60 | 0/5 | ||
| Control | PBS | 14/14 | |
| Whole IgG fractions (BP-IgG) | Fab-B4 | 30 | 0/4 |
| 30 (24 hours later) | 1/5 | ||
| Control | PBS | 4/4 |
Neonatal COL17 humanized BP model mice were injected with either COL17 NC16A-affinity purified BP autoantibodies (BPAbs: 50 μg/g body weight) or whole IgG fractions (BP-IgG: 1 mg/g body weight) from patients with bullous pemphigoid. The mice were then treated immediately or 24 hours later (underlined) with Fabs by intraperitoneal injection. For Fab combination therapy, the total dose comprised one third of each Fab clone.